Browse the evidence

Ex-DARPin fusion proteins injected at 25 nmol/kg every three days significantly lowered blood glucose, inhibited food consumption, and reduced body weight for 30 days in STZ-induced diabetic mice.

Ex-DARPin fusion proteins may be a promising treatment for managing blood glucose and weight in diabetic patients.

Ex-DARPin fusion proteins have a comparable half-life of 29-32 hours, which is much longer than that of native Ex (0.5 hours in rats).

Longer half-life of Ex-DARPin fusion proteins may reduce the frequency of administration needed for effective treatment.

Ex-DARPin fusion proteins significantly improved the survival of pancreatic islets in diabetic mice.

Improving pancreatic islet survival could enhance insulin production and overall diabetes management.

There are currently no clear guidelines for the prehabilitation of obese patients with dysglycemia undergoing bariatric surgery.

Healthcare providers should recognize the need for developing guidelines for prehabilitation in this patient population.

Patients with coronary artery disease (CAD) have a lower capillary-to-fiber ratio (C/Fi) and capillary-to-fiber perimeter exchange (CFPE) index in Type II fibers compared to healthy controls.

Understanding these differences can inform targeted rehabilitation strategies for CAD patients.

Measured daily average CO2 production rates were not significantly different between the diets.

Dietary composition may not significantly affect metabolic rates as measured by CO2 production.

30% of steep losers died during postintervention follow-up versus 10-18% in other trajectories.

Monitoring for excessive weight loss is crucial, especially in older adults with diabetes.

Challenges in ensuring safety, tolerability, and equitable access are critical barriers to advancing anti-obesity pharmacotherapy.

Address these barriers to improve obesity treatment outcomes.

Promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity.

Practitioners should be aware of safety concerns associated with certain GLP-1 receptor agonists.

Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, offer substantial potential due to their oral bioavailability and favorable gastrointestinal tolerability.

Practitioners may consider these candidates for their potential benefits in treatment regimens.

Obesity is projected to affect 3.8 billion people worldwide by 2050.

Practitioners should be aware of the increasing obesity trend and its implications for health.

There is a complex and bidirectional relationship between adipose and breast tissues.

Understanding this relationship can help in developing targeted interventions for breast cancer.

The global prevalence of obesity has risen sharply during the past half-century, reaching pandemic proportions.

Clinicians should be aware of the increasing obesity rates as a public health concern.

Conventional drug therapies explored in OSA have generally produced disappointing results.

Practitioners should be aware that current drug therapies for OSA may not be effective.

GLP-1RAs probably have little or no effect on risk for thyroid cancer.

Practitioners should consider that GLP-1RAs may not significantly increase thyroid cancer risk based on current evidence.

GLP-1RAs may have little or no effect on pancreatic cancer risk.

Practitioners should be aware that GLP-1RAs may not significantly increase pancreatic cancer risk.

There is no clear evidence that GLP-1RAs and dual GLP-1/GIPRA enhance cardiorespiratory fitness (CRF).

Practitioners should be cautious in expecting improvements in CRF from these therapies.

Cardiovascular-Renal-Hepatic-Metabolic diseases are increasing globally, posing significant challenges for patient care and clinical research.

Healthcare providers should be aware of the increasing prevalence of these diseases.

There is no significant change in resting state functional connectivity (RSFC) after the semaglutide intervention compared to the placebo group in the investigated regions of interest (ROIs).

Practitioners can consider that semaglutide does not significantly alter RSFC related to suicidal ideation and behavior in this population.

The change in RSFC between visits did not differ significantly between the groups.

This indicates that semaglutide does not lead to significant changes in RSFC over the study period compared to placebo.

There were no effects on diet quality for the 'tax' and 'healthier substitute offers.'

Strategies such as taxing unhealthy foods and offering healthier substitutes may not improve diet quality.

Increases in inflammatory markers from training do not correlate with any outcome variable.

Training-induced inflammation does not impact performance outcomes.

Recent innovations in obesity diagnosis include bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) scans, alongside emerging biomarkers from 'omics' technologies.

Healthcare practitioners should consider incorporating BIA and DXA scans for more accurate obesity diagnosis.

OXT/GLP-1 co-administration increases c-Fos expression in the PVN and supraoptic nucleus.

Increased neuronal activation in specific brain regions may underlie the effects on food intake and body weight.